Drugs / TevaGastrim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01542944 | Feb 2012 → Apr 2016 | acute myeloid leukemia, myelodysplastic syndrome | Sheba Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TevaGastrim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01542944 ↗ |
| Modality | Protein / enzyme biologic | “TevaGastrim which is a biosimilar version of Filgrastim recombinant human G-CSF (G-CSF)” NCT01542944 ↗ |